Report predicts $5.5B radiopharma market by 2017: http://www.auntminnie.com/index.aspx?sec=ser&sub=def&pag=dis&ItemID=102995
"The report estimates that Tc-99m diagnostic procedures are expected to
increase by more than 15% in mature markets of North America, Europe,
Japan, South Korea, and Asia-Pacific nations between 2010 and 2030.
However, a shortage of molybdenum-99, the precursor to Tc-99m, has been a
threat to this industry. Also, the high cost of devices using
radioisotopes, short half-lives, lack of good manufacturing practices,
and stringent regulatory approvals are major hurdles to growth of the
market, according to the report. The scheduled shutdowns of the
National Research Universal (NRU) reactor in Canada in 2016 and the
Osiris reactor in France in 2018 pose major risks for manufacturers in
the near future, MarketsandMarkets noted. However, radiopharmaceutical
companies have increased the production of thallium to meet the
shortage, as it is the radiopharmaceutical most commonly used as a
substitute for technetium-99 in cardiac stress tests."
Welcome to the Future of Neutron Scattering in Canada
a grassroots, nonpartisan movement of ordinary Canadians
that emerged in response to the lack of commitment by federal government(s) to build a new research reactor in Canada for nearly 2 decades.